DexCom, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
8.8
Very Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
DXCM
Consensus analyst target of $83.92 is 37% above current price.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $83.92 (+36.8%)
24 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
DXCM
MRK
26.3×
Trailing P/E
31.5×
20.1×
Forward P/E
11.5×
19.3%
Profit Margin
13.6%
61.5%
Gross Margin
76.6%
35.6%
ROE
—
15.0%
Revenue Growth
4.9%
91.9%
Earnings Growth
—
—
Beta
0.28
—
Price / Book
—
$23.7B
Market Cap
$277.0B
$54 – $90
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →